China's first cancer early screening registration certificate was approved, early screening market ushered in a new change

Hangzhou, November 25, 2020 - Nohui Health, China's first bio-high-tech company focused on cancer early screening, today held a press conference at the company's Hangzhou headquarters, "The First Certificate of Cancer Early Screening in China", with cross-border leaders from clinical front-line, national and Zhejiang cancer centers, medical examination institutions and artificial intelligence to deeply analyze and explore the important value of cancer early screening.
the "main character" of this launch is Nohui Health's non-invasive home use of colorectal cancer early screening products Chang Weiqing? The National Drug Administration (NMPA) approved the product's application for registration of innovative three types of medical devices on November 9th, and made it clear that Chang Weiqing should be used in the expected use. Suitable for screening of people at high risk of colorectal cancer aged 40-74 years.
"This is China's first and only cancer early screening product registration certificate approved by the State Drug Administration.
, director of drug safety at the Zhejiang Provincial Drug Administration, called to fully affirm Nohui's healthy sense of innovation and innovation ability, hoping that the company on the one hand to do a good job in the promotion and application of innovative products.
, give full play to the advantages of the company's product innovation capabilities and mechanisms, adhere to the road of product innovation, in order to promote the high-quality development of the medical device industry in Zhejiang Province to make more contributions.
Professor Zheng Shu, Director of the Academic Committee of Zhejiang University Oncology Research Institute, Professor Zhao Ping, Chairman of the China Cancer Foundation, Professor Ding Kefeng, Vice President of the Second Hospital affiliated with Zhejiang University Medical College, Mr. Zhang Ligang, Founder, Chairman and CEO of Aikang Group, Director of oncology Department, Jiangsu Provincial People's Hospital, Gu Yan Professor Hong, Vice Minister of The Academic Department of the China Cancer Foundation, Zhai Zhenhua, Ai Cheng, founder of iAsk, Mr. Zhu Yeqing, co-founder and CEO of Nohui Health, and Dr. Chen Yiyou, Chief Scientist of Nohui Health, witnessed the release of the first evidence of early screening of cancer in China.
Image caption From left to right Ai Cheng, Zhai Zhenhua, Gu Yanhong, Zhao Ping, Zheng Shu, Ding Kefeng, Zhang Ligang, Chen Yiyou, Zhu Yeqing Sun Yat-sen University Cancer Prevention and Control Center Senior Chief Expert Professor Wan Desen, Professor Zhang Suzhen, Director of the Institute of Oncology, Zhejiang University, Professor Wang Guiqi, Director of Endoscopy Department of the Chinese Academy of Medical Sciences/National Cancer Center, Professor Cai Sanjun, Director of The Oncology Hospital of Fudan University Professor Gu Jin, Chief Physician of the Hospital, Professor Wang Xishan, Director of Colorectal Surgery, National Cancer Center of the Chinese Academy of Medical Sciences, Professor Zeng Qiang, Director of the Institute of Health Management of the Second Medical Center of the PLA General Hospital, Professor Chen Wanqing, Director of the Office of Early Cancer Diagnosis and Treatment of the Oncology Hospital/National Cancer Center of the Chinese Academy of Medical Sciences, and Professor Dai Min, Director of the International Exchange Department of the Chinese Academy of Medical Sciences, delivered a video message to the "China Cancer First Certificate".
" Nohui Health adhered to seven years, more than 100 million U.S. dollars of investment, 16 months to complete China's first cancer early screening registered clinical trials, all of which finally achieved Chang Weiqing? Approved by the State Drug Administration of China's cancer early screening first certificate.
this is an important milestone in the healthy development of Nohui, but also the glory of Nohui's health, we are honored to witness the cause of early screening of cancer in China this important historical moment.
"We are deeply grateful to every leader, expert and partner who has worked with Nohui Health, and we are deeply grateful to every user and family who uses Nohui Health products," said Yeqing Zhu, co-founder and CEO of Nohui Health.
to change the individual, change the family's life trajectory, is this first heart to lead us to stick to today, lead us to harvest all the way sunshine, but also lead us to take every step, towards a broader future. At the
" press conference, Dr. Chen Yiyou, Chief Scientist of Nohui Health, on behalf of the company, donated RMB 1 million to the Zhengshu Oncology Development Fund of Zhejiang University Education Foundation Medical College, in honor of professor Zheng Shu, the 90-year-old "first person in China for early screening of colorectal cancer".
donation will be decided by Professor Zheng Shu to invest in the training and academic research of colorectal cancer.
held a special session of cross-border competition at the launch.
Innovation Engineering Chairman and CEO Kaifu Li, Aikang Group Founder, Chairman and CEO Zhang Ligang, Zhejiang University School of Medicine affiliated with the Second Hospital Vice President Ding Kefeng, Nohui Health Co-Founder and CEO Zhu Yeqing four guests under the auspices of Ai QAsk founder Ai Cheng, cross-border discussion of "who is the end of cancer."
, who has successfully battled cancer, says he agrees with his doctor's advice: "Early cancers are usually asymptomatic and must be detected through an early screening."
if everyone over the age of 50 were able to have an annual cancer screening, the risk of cancer could be greatly reduced.
" Professor Ding Kefeng admits that he is getting more and more patients through surgery every year, but that's not what doctors and patients want to see, and what they really want is an effective way to keep patients from getting less cancer.
Ligang said, 10 years ago we could not run cancer, now it is possible to run over cancer.
cases in which Chang Weiqing, a medical examiner of Aikang, was screened positive, the average user under the age of 40 was pre-cancerous, and early detection of bowel cancer was preventable and curable.
Zhu said that the family is a key place to care for health.
Health China 2030 Planning Outline pointed out that cancer prevention and treatment should move forward, the center of gravity sank.
should not only move forward to the primary health care institutions, but also to the family.
hope that through early screening of cancer to eliminate cancer outside the hospital, eliminate in the bud, so that China's 120 million people at high risk of colorectal cancer can really benefit.
conference will be clearly defined and discussed in depth the definition and value of early screening for cancer.
Ping, president of the China Cancer Foundation, said the focus of colorectal cancer prevention and treatment is on early diagnosis and treatment, and the rate of early diagnosis of colorectal cancer can exceed 90%.
Professor Gu Yanhong, deputy director of the oncology department of Jiangsu Provincial People's Hospital, once believed that the core of early diagnosis and treatment of cancer lies in early diagnosis and treatment, treatment of colorectal cancer pre-cancer lesions cost 20,000 yuan, while the treatment cost of late stage (phase 4) is more than 250,000 yuan, Chang Weiqing? The negative prediction value of colorectal cancer reached 99.6%, which has excellent practical value of early screening.
, founder, chairman and CEO of Aikang Group, said, Chang Weiqing? Early cancer screening is very effective, not only to improve the compliance of the colonoscopy, but also to effectively detect pre-cancer lesions of bowel cancer.
Ding Kefeng, project leader of the "Clear-C" clinical research project and vice president of the Second Hospital affiliated with Zhejiang University School of Medicine, affirmed Chang Weiqing from the perspective of clinical research. The important value of screening for malignant tumors in China.
In a media exchange, Nohui Health co-founder and CEO Zhu Yeqing suggested that early screening may be the largest piece of cake used in the whole genetic testing field for cancer, with 120 million high-risk people in China, the dividends of an aging population and the risks of the medical market over the years society enough to show the space and value of the products in the early screening market.
future, Nohui Health will continue to support innovative new technologies to further expand product applications through large-scale clinical practices.
china's health sector is a long track, and most of China's investment over the next 30 years will revolve around health.
About Nohui Health, founded in 2015, is a pioneer in the colorectal cancer screening market in China, as well as a leader in early screening for cancer in China and a pioneer in home testing.
company's vision is to achieve cancer prevention and cure through screening and early detection.
Health holds the first cancer early screening registration certificate approved by the State Drug Administration, and its two colorectal cancer screening products (Chang Weiqing? And the tube? Has been approved by the State Drug Administration and has been commercialized.
addition, the company has two in-process product pipelines for gastric and cervical cancer screening.
owns global ownership of all of its listed and pipeline products.
Chang Weiqing? As China's first and only cancer early screening product approved by the State Drug Administration, using multi-target FIT-DNA joint detection technology, is a non-invasive home-used colorectal cancer early screening test, for Chinese groups of gene design, access to a number of national authoritative clinical consensus recommendations, for China's 120 million people at high risk of colorectal cancer.
the tube? China's first home self-testing blood (FIT) testing products, has been approved by the State Drug Administration and the European Union CE certification, for China's 630 million mass market, to help effectively identify the high-risk groups of colorectal cancer.
Nohui Health Headquarters is established in Hangzhou, in Beijing, Hangzhou and Guangzhou has a total of 20,000 square meters of third-party medical laboratory, and with hospitals, medical examination centers, insurance companies, pharmacies and online channels extensive cooperation, so that our users can easily, comfortably and accurately enjoy home testing services, early warning of cancer risk, effective prevention of cancer.
Bioaversing Source: Biological Exploration Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mays Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here